Noninferiority is almost certain with lenient noninferiority margins.

[1]  J. Ioannidis,et al.  Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. , 2015, Journal of clinical epidemiology.

[2]  T. Perneger,et al.  Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting. , 2015, Journal of clinical epidemiology.

[3]  V. Prasad,et al.  Non-inferiority trials: why oncologists must remain wary. , 2015, The Lancet. Oncology.

[4]  N. Desai,et al.  Reporting of noninferiority trials in ClinicalTrials.gov and corresponding publications. , 2015, JAMA.

[5]  J. V. van Delden,et al.  Phase IV non-inferiority trials and additional claims of benefit , 2013, BMC Medical Research Methodology.

[6]  I. Hozo,et al.  Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials , 2013, PloS one.

[7]  Shiro Tanaka,et al.  Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review , 2012, Clinical Cancer Research.

[8]  J. Vandenbroucke,et al.  Reporting of noninferiority trials was incomplete in trial registries. , 2011, Journal of clinical epidemiology.

[9]  J. Vandenbroucke,et al.  Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. , 2010, International journal of epidemiology.

[10]  Kenneth D. Mandl,et al.  Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov , 2010, Annals of Internal Medicine.

[11]  Iztok Hozo,et al.  Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. , 2008, Archives of internal medicine.